There was a trend that did not reach statistical significance toward improved response rates among patients with a history of prior HSCT (adjusted OR, 5.175; P = .079).
← all excerpts
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia.
1
0.0790
0.0790